This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Pancreatic cancer is one of the most challenging diseases to treat, and while survival rates have improved since the 1970s, they have plateaued in recent years. But two promising drugs in the pipeline ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen. Ben Sasse this week said he's taking daraxonrasib.

Former Sen. Ben Sasse (R-Neb.) detailed his battle with cancer and reflected on his life during a wide-ranging interview with The New York Times’s Ross Douthat. The conversation, released Thursday as ...

Raphael was believed to be 17 when he did this chalk sketch, likely a self-portrait. "What is really extraordinary is the perfection of his technique in drawing," said curator Carmen Bambach. You can ...

After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic cases of the ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the ...

Current drugs for pancreatic cancer lose effectiveness within months because the tumor becomes resistant. Now, a group from Spain's National Cancer Research Centre (CNIO) has been able to avoid the ...

Researchers in Spain have developed a new therapy protocol that could revolutionize the treatment of pancreatic cancer. Notoriously aggressive and difficult to treat, pancreatic cancer is rarely ...